Neurocrine Biosciences Inc. (NASDAQ:NBIX) insider Christopher Flint Obrien sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $52.84, for a total value of $1,321,000.00. Following the completion of the sale, the insider now directly owns 30,044 shares of the company’s stock, valued at $1,587,524.96. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Neurocrine Biosciences Inc. (NASDAQ:NBIX) opened at 52.27 on Friday. The company’s market capitalization is $4.54 billion. Neurocrine Biosciences Inc. has a 52 week low of $31.25 and a 52 week high of $58.46. The stock’s 50 day moving average is $46.84 and its 200 day moving average is $47.90.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.14. During the same period last year, the business earned ($0.40) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. Analysts predict that Neurocrine Biosciences Inc. will post ($1.68) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

A number of analysts have recently commented on the company. Jefferies Group reaffirmed a “buy” rating and issued a $61.00 price target on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $72.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a research note on Thursday, October 27th. HC Wainwright reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a research note on Friday, August 5th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $96.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 22nd. Finally, Cowen and Company reissued a “buy” rating and set a $65.00 target price on shares of Neurocrine Biosciences in a research note on Friday, August 5th. Two research analysts have rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $69.09.

Several hedge funds have recently made changes to their positions in NBIX. Price T Rowe Associates Inc. MD raised its position in Neurocrine Biosciences by 1.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 9,364,314 shares of the company’s stock worth $474,209,000 after buying an additional 169,460 shares in the last quarter. Perceptive Advisors LLC raised its position in Neurocrine Biosciences by 2.8% in the second quarter. Perceptive Advisors LLC now owns 2,797,967 shares of the company’s stock worth $127,167,000 after buying an additional 77,000 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Neurocrine Biosciences by 6.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,150,949 shares of the company’s stock worth $108,924,000 after buying an additional 136,277 shares in the last quarter. BlackRock Fund Advisors raised its position in Neurocrine Biosciences by 3.3% in the third quarter. BlackRock Fund Advisors now owns 2,009,633 shares of the company’s stock worth $101,768,000 after buying an additional 64,921 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Neurocrine Biosciences by 32.8% in the second quarter. Franklin Resources Inc. now owns 1,541,446 shares of the company’s stock worth $70,059,000 after buying an additional 380,841 shares in the last quarter. 97.37% of the stock is currently owned by hedge funds and other institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.